New York Times cites UC research in story about second-and thirdhand smoke
Health columnist Jane E. Brody quotes University of Cincinnati professors as she makes the case that parents should keep their children out of places smoking is permitted
Research penned by University of Cincinnati faculty members inspired The New York Times personal health columnist Jane E. Brody to write about the ongoing threat posed by second- and thirdhand smoke to the health of children exposed to them.
In "The Risks to Children From Adults Who Smoke," Brody makes the case that children should be kept away from places where smoking is permitted, even if no one is smoking at a given time.
"Wise parents should keep their children out of any environment where smoking is allowed, even if no one is smoking there at the time," Brody writes. "The reason? Growing concern about the potential harms caused by exposure to the nicotine and other tobacco toxicants in thirdhand smoke that linger in the environment long after the smoke is gone."
Brody's argument relies on published research by UC faculty members about the effects of chronic tobacco exposure on children in both the short and long term. First she cites the work of Dr. E. Melinda Mahabee-Gittens and colleagues at UC, published in March 2017 in Tobacco Control. Mahabee-Gittens and company discovered that the residue from secondhand smoke accumulates on smokers and the surfaces in the vicinity of where they smoke, and that those toxicants can easily get on children's hands and into their bodies.
She also quotes human services professor Ashley L. Merianos, whose research published recently in Pediatrics finds that as little as one hour of exposure to secondhand smoke per week can have a significant impact on the health of adolescents.
Brody is among the most prominent health writers in the world, having served in her role as personal health columnist for The New York Times since 1976. Her widely read column appears in The Times' Science Times section and in numerous newspapers across the country.
A research powerhouse
The University of Cincinnati is classified as a Research I institution by the Carnegie Commission, and is ranked in the National Science Foundation's top 35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Learn more about advanced degrees at UC.
Related Stories
Three years, countless stories
May 15, 2026
UC's Klekamp Law celebrates its 193rd Hooding with stories from graduates reflecting on their paths through the college.
Driven by curiosity, guided by care
May 14, 2026
Max Wilson, a University of Cincinnati College of Allied Health Sciences health sciences major on the pre-physician assistant track, found his path expanding beyond the classroom and into hands-on research focused on human performance and patient care.
UC Blue Ash celebrates top students and recognizes Honor Student of the Year
May 14, 2026
The University of Cincinnati Blue Ash College recently hosted a special event that celebrated students for exceptional achievements during the 2025-26 academic year. The honorees included academic award winners, student engagement award winners, Latin Honors graduates, and the 2026 UC Blue Ash College Honor Student of the Year.
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
University of Cincinnati graduate programs rise in national rankings across high-demand fields
May 13, 2026
University of Cincinnati graduate programs climbed in the latest U.S. News & World Report rankings, led by strong gains in workforce-focused fields including public health, clinical psychology and business.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.